Drug intelligence / Profile preview

SP5M002

Development stage: Unknown
Lead developer: Shinpoong Pharma
Administration: Intraarticular

Overview

SP5M002 is a novel intra-articular viscosupplement developed by Shin Poong Pharmaceutical for the treatment of knee osteoarthritis. It is composed of hyaluronate cross-linked with hexamethylenediamine (HMDA), a modification designed to enhance the stability and viscoelastic properties of the gel compared to conventional cross-linking agents like 1,4-butanediol diglycidyl ether (BDDE). By supplementing the synovial fluid, SP5M002 provides mechanical lubrication and shock absorption within the joint, thereby reducing pain and improving mobility in patients with mild to moderate osteoarthritis. It is currently being evaluated in Phase III clinical trials as a long-acting treatment option.

Other names: hexamethylenediamine cross-linked hyaluronateHMDA cross-linked hyaluronate

Beyond the preview

Go deeper on SP5M002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP5M002.

Explore the full profile